anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
A method of preparing a biocompatible polymeric coating includes preparing an aqueous polymer solution by contacting and reacting methacrylic acid and at least one methacrylate or phosphorylcholine. The methacrylate or phosphorylcholine may include hydroxyethyl methacrylate, polyethylene glycol monomethacrylate, or methacryloyloxyethyl phosphorylcholine. An aqueous coupling agent solution is prepared and is either applied to the substrate surface or is mixed with the polymer solution to form a coating solution. If the coupling agent solution was first applied to the substrate surface, the polymer solution is then applied to the primed substrate surface. Alternatively if a coating solution was created, the coating solution is applied to the substrate surface. In either event, the polymer solution and coupling agent solution react with the substrate to form the biocompatible polymeric coating on the substrate surface.
A first object of the invention is to provide administrable dual MRI contrast enhancing compositions containing as key components, at least (a) one positive paramagnetic metal chelate contrast agent and at least (b) one negative ferromagnetic or superparamagnetic contrast agent. These compositions distinguish the prior art by the properties of the said components toward the cell membrane barrier. Actually, either one of (a) and (b) predominantly internaliyes tissue, whereas the remaining one is predominantly retained in the circulation, this being for a time sufficient to provide shart MRI images of the circulation in said tissue. Typically, either one of (a) and (b) is predominantly intra-vascular while the other one is predominantly extra-vascular or is rapidly removed from the circulation by macrophages. Then, after removal from circulation it internalizes neighboring tissue. The transfer from vessels to tissues is effected by RES mediated phagocytosis. Alternatively, an extravascular compound may cross the vessel walls and distribute randomly extracellularly. Another object of the invention is to provide is to provide a dual blood pool contrast medium comprising a positive MRI contrast agent (a) mainly shortening the T1 relaxation response and a negative contrast agent (b) mainly shortening the T2 relaxation response, both relaxation effects of (a) and (b) being controllable at will.
FIELD: medicine. SUBSTANCE: method involves applying plastic repair of brain tissues by means of delivering pharmacological preparations and plastic repair material obtained from nerve tissue, into pathological focus. Combined intraorganic bioengineering action composed of pharmacological, plastic repair and bioinformation manipulations is used as plastic material for this procedure. Mammal embryo neuron preparation is applied as plastic repair material biocompatible with biological fluid of patient when considering the electromagnetic field properties and blood group. Preparation and material delivery is carried out by means of selective intra-arterial transfusion. Information control of patient state and right application of plastic repair and curative measures are carried out by means of continuous monitoring of venous blood and liquor discharged from lesion focus. EFFECT: wide range of applications at the biomolecular and bioinformation level. 5 cl
The objective of this human randomized, double blind, placebo-control (RDBPC) study is to evaluate the efficacy of a 0.2% chlorhexidine (CHX) gel on reducing bacterial load and peri-implant inflammation at implant-abutment interface during the early healing stage. Thirty-six healthy patients (mean age 52,28 years; range 29-75 years) without a significant past medical anamnesis, all non-smokers, will be recruited as candidates for single implant placement and prosthetic rehabilitation.Patients will be randomly divided in group A (control) and group B (test) as indicated by the randomization chart. The randomization of this prospective, randomized-controlled, double blind study was obtained using computer generated random numbers, centralized with sequentially sealed opaque envelopes provided by the study adviser.The surgeon will open the sealed envelope containing the randomized group only after having inserted the implant.During the first evaluation, all subjects will be clinically examined: radiographs, plaque and bleeding scores would be carried out for diagnostic evaluation; then the patients would be scheduled for surgery procedures. All Implants (Cortex classic, Shalomi, Israel) would be inserted by two skilled operators who will follow a two-stage protocol and would place them according to the manufacturer's instructions. Before surgery all the patients would be subject to applications of chlorhexidine digluconate solution 0.2% for 2 minutes to obtain lower bacterial load and local anesthesia would be given with Articaine® (Ubistesin 4% - Espe Dental AG Seefeld, Germany) associated with epinephrine (1:100.000). Eventually, all patients would be rehabilitated with a single implant-supported crown. During all the stages either a gel containing 0.20% CHX (Plak ®Gel; Polifarma Wellness Srl, Rome, Italy) or a placebo gel (Placebo, Polifarma Wellness Srl, Rome, Italy) would be used. The two gels are perfectly alike in packaging, colour and smell and nobody knows the exact location of placebo or test gel, which would be revealed, only after data collection would be performed, by the person who prepared them. A or B gel would be placed on the internal connection abutments and then a cover screw would be inserted. Finally, the site would be sutured with non-absorbable nylon sutures. Cone Beam Computed Tomography evaluation (CBCT) (VatechIpax 3D PCH-6500, Fort Lee, NJ USA) would be performed both for pre-operative and post-surgical implant placement. All patients will recieve antibiotic therapy, 2g/day for 6 days (Augumentin®; Glaxo-Smithkline Beecham, Brentford, UK).The post-operative pain would be controlled with NSAIDs, and oral hygiene instructions would be given. Both gels would be given to the patients, according to the protocol, and applied 2 times/day until suture removal after 7 days. Soft tissue biopsies would be performed by means of a circular scalpel (5.5 mm in diameter) at the implant insertion (T0) and after two months of healing (second stage surgery)(T1) to analyze the peri-implant inflammatory infiltrate and the micro-vessel density (MVD) in both groups.
The invention discloses a Chinese traditional medicine composition for the treatment of cataract by internal administration and belongs to the Chinese traditional medicine field. The invention can conquer the existing deficiencies of the operation curing methods. The raw material drugs producing the effective component in weight are that: 10g of semen plantaginis, 10g of cassia seed, 6g of feather cockscomb seed, 10g of motherwort fruit, 10g of medlar, 15g of south dodder seed, 8g of fruit of Chinese magnoliavine and 10g of pipewort flower. The drug can be takeen by frying with water and one dosage each day and twice per day. The invention has the functions for promoting blood circulation and freeing channels, increasing exudation of lens albumen hydrolyze enzyme and recovering the normalization of microcirculation on eye part by the synergism of drug effects after mixing the drugs. And the invention can clear and nourish liver and cut off the main inducements of cataract generation, get notable effects during the curing process of cataract in initial and middle periods without recurring after cure.
No intervention provided. These participants will receive access to the Go! Foods for You program after the research trial has been completed (12 weeks after registration).
PURPOSE:To provide a renal failure-improving agent containing (+)catechin as an active ingredient and having an uremic substancelowering action. CONSTITUTION:(+)-Catechin of the formula is added as an active ingredient. The (+)-catechin can be extracted from a galenical Rheum spp., tea leaves, etc., and has extremely low toxicity and high safety. The (+)-catechin can be prepared as such or together with the conventional carrier into oral agents such as tablets, capsules, granules or grains or into parenteral agents such as injections or suppositories. The administration amount of the (+)-catechin is 100mg-6g several times a day on oral administration or 1-100mg a day on parenteral administration such as intravenous injection, drip intravenous injection, hypodermic injection and intramuscular injection. The agent is a preservative treating agent capable of inhibiting the progress of chronic renal failures and of preventing or retarding the introduction of dialysis.
The present application relates to systems and methods for reliable and scalable health monitoring. A health monitoring system and method are disclosed. The health monitoring system and method includes a sensory system and a sensory to front end communication (SFCM) protocol coupled to the sensory system. The health monitoring system and method include a front-end system coupled to the sensory system and a front-end to back-end communication (FBCM) protocol coupled to the front-end system. The health monitoring system and method includes a back-end system. The SFCM protocol communicates with the front-end system using a first state awareness link and the FBCM protocol communicates with the back-end system using a second state awareness link.
Tennis elbow patients usually experience diminished grip strength, decreased functional activities, and increased pain, all of which can have a significant impact on everyday activities. Tennis elbow can also be caused by excessive elbow use. The following is a description of the basic clinical manifestation of tennis elbow, as well as the most commonly reported symptoms of people suffering from the condition: Tennis elbow is easily identified and confirmed with a test that produces discomfort, palpable tenderness over the lateral epicondyle facet, resisted wrist extension, resisted middle finger extension, and passive wrist flexion. Tennis elbow is a common elbow disease caused by excessive use. Furthermore, despite some difficulty, the patient must be able to extend his or her wrist and middle finger. The goal of this study is to find out how Mulligan Mobilization with and without myofascial release affects pain, grip strength, and function in people with lateral epicondylitis in the short and long term.

Mulligan mobilisation and myofascial release have both been shown to be effective treatments for lateral epicondylitis. The purpose of this study is to look into the short-and long-term advantages of myofascial release and Mulligan mobilisation. No research has been conducted to evaluate whether mulligan mobilisation with or without myofascial release benefits people with lateral epicondylitis in terms of pain, grip strength, and overall function. This study will not only help therapists come up with treatment goals for lateral epicondylitis, also known as tennis elbow, but it will also add credibility to the existing body of literature.
INTRODUCTION: Mosquito-borne diseases represent a global public health concern and are responsible for over 700 000 deaths globally every year. Additionally, many mosquito species have undergone a dramatic global expansion due to various factors, including climate change, and forecasts indicate that mosquito populations will persist in dispersing beyond their present geographic range, namely in temperate climates. The research literature on this topic has grown in recent years, including some systematic evidence synthesis. However, to provide a comprehensive overview of this growing literature needed for policy action, a summary of this evidence, including existing systematic reviews, is required. This study aims to undertake an umbrella review that explores the impacts of climate change on the emergence and reemergence of diseases transmitted by mosquitoes in temperate zones and the publication of the protocol is a fundamental step to ensure the credibility, transparency and reproducibility of this research.
METHODS AND ANALYSIS: Studies published in scientific journals indexed by PubMed, EMBASE, Cochrane Library, Epistemonikos, and Web of Science Core Collection to be included in this umbrella review will meet the following criteria: the topic of study (climate change and mosquito-borne diseases), regions (temperate zones), study designs (systematic reviews and meta-analysis), language (any) and date (since inception until December 31st, 2023). Titles and abstracts from selected articles will be evaluated by two authors independently and any discrepancy will be resolved through consensus or, if not possible, through a third author. The data will be extracted, and the risk of bias will be evaluated. The quality of the methodology of the included reviews will be assessed using AMSTAR 2. A narrative synthesis will examine the included systematic reviews. The quality of evidence for all outcomes will be judged using the Grading of Recommendations Assessment, Development and Evaluation working group methodology.
The present invention discloses an acyclovir drug resin bioadhesive slow release liquid preparation which is an antiviral drug and is admitted once during one day, and a preparation method of the acyclovir drug resin bioadhesive slow release liquid preparation. The preparation contains acyclovir and polymers which can be accepted on the aspect of pharmacology. According to the weight percentage, the preparation contains 30 to 90% of acyclovir, 10 to 70% of auxiliary materials, and auxiliary materials as the rest. The auxiliary materials having a slow-release function are ation exchange resin and ethyl cellulose and/or acrylic resin. The auxiliary material having an adhesive function is hydroxypropyl methylcellulose. Compared with a quick release preparation, the slow release preparation of the present invention can keep effective blood drug level within 24 hours and enhance the curative effects, and has the advantages of less toxic side effect, convenient administration and carrying, and reduced administration time. The preparation needs to be admitted once during one day. The acyclovir drug resin bioadhesive slow release liquid preparation of the present invention can be used as an antiviral drug.
PURPOSE: To detect the presence of inflammation in a patient by measuring cICAM-1 in one or more patient's humor samples, and comparing its amount with normal standard value for one or more types of assayed body fluids. CONSTITUTION: The amount of cICAM-1 in one or more types of patient's humor samples is measured, and the amount of the cICAM-1 in the sample is compared with normal standard value for one or more types of assayed humor. The amount of the high cICAM-1 exceeding the normal amount is the index of the presence of inflammation. Preferably, useful assay is immunoassay for detecting the presence of the inflammation in the patient. The assay is brought into contact with first antibody capable of bonding one or more types of patient's humor sample to the cICAM-1 and labeled second antibody capable of being bonded to the cICAM-1. As the scale of the amount of the cICAM-1 in the sample, the amount of bonded labeled second antibody is measured. The amount of the cICAM-1 in the sample is compared with the standard amount of the normal cICAM-1 for the one or more types of assayed humor.  Preferably, the antibody is monoclonal antibody.
OBJECTIVE: Obesity is a key predictor of type 2 diabetes (T2D). However, metabolic complications are not solely due to increased BMI. We hypothesized that differences between genetically predicted BMI and observed BMI (BMI-diff) could reflect deviation from individual set point and may predict incident T2D.
RESEARCH DESIGN AND METHODS: From the UK Biobank cohort, we selected participants of European ancestry without T2D (n = 332,154). The polygenic risk score for BMI was calculated via Bayesian regression and continuous shrinkage priors (PRS-CS). According to the BMI-diff, the 10-year risk of T2D was assessed using multivariable Cox proportional hazards model. Independent data from the Korean Genome and Epidemiology Study (KoGES) cohort from South Korea (n = 7,430) were used for replication.
RESULTS: Participants from the UK Biobank were divided into train (n = 268,041) and test set (n = 115,119) to establish genetically predicted BMI. In the test set, the genetically predicted BMI explained 7.1% of the variance of BMI, and there were 3,599 T2D cases (3.1%) during a 10-year follow-up. Participants in the higher quintiles of BMI-diff (more obese than genetically predicted) had significantly higher risk of T2D than those in the lowest quintile after adjusting for observed BMI: the adjusted hazard ratio of the 1st quintile (vs. 5th quintile) was 1.61 (95% CI 1.26-2.05, P < 0.001). Results were consistent among individuals in the KoGES study. Moreover, higher BMI than predicted was associated with impaired insulin sensitivity.
CONCLUSIONS: Having a higher BMI than genetically predicted is associated with an increased risk of T2D. These findings underscore the potential to reassess T2D risk based on individual levels of obesity using genetic thresholds for BMI.
BACKGROUND: We have previously identified an unsuspected role for GJB3 showing that the deficiency of this connexin protein induces aneuploidy in human and murine cells and accelerates cell transformation as well as tumor formation in xenograft models. The molecular mechanisms by which loss of GJB3 leads to aneuploidy and cancer initiation and progression remain unsolved.
METHODS: GJB3 expression levels were determined by RT-qPCR and Western blot. The consequences of GJB3 knockdown on genome instability were assessed by metaphase chromosome counting, multinucleation of cells, by micronuclei formation and by the determination of spindle orientation. Interactions of GJB3 with α-tubulin and F-actin was analyzed by immunoprecipitation and immunocytochemistry. Consequences of GJB3 deficiency on microtubule and actin dynamics were measured by live cell imaging and fluorescence recovery after photobleaching experiments, respectively. Immunohistochemistry was used to determine GJB3 levels on human and murine bladder cancer tissue sections. Bladder cancer in mice was chemically induced by BBN-treatment.
RESULTS: We find that GJB3 is highly expressed in the ureter and bladder epithelium, but it is downregulated in invasive bladder cancer cell lines and during tumor progression in both human and mouse bladder cancer. Downregulation of GJB3 expression leads to aneuploidy and genomic instability in karyotypically stable urothelial cells and experimental modulation of GJB3 levels alters the migration and invasive capacity of bladder cancer cell lines. Importantly, GJB3 interacts both with α-tubulin and F-actin. The impairment of these interactions alters the dynamics of these cytoskeletal components and leads to defective spindle orientation.
CONCLUSION: We conclude that deregulated microtubule and actin dynamics have an impact on proper chromosome separation and tumor cell invasion and migration. Consequently, these observations indicate a possible role for GJB3 in the onset and spreading of bladder cancer and demonstrate a molecular link between enhanced aneuploidy and invasive capacity cancer cells during tumor cell dissemination.
The participants will undergo the Naptime Protocol. The study team will provide a 4 hour period nightly during which patient room activity, light levels and noise levels will be decreased. The team will monitor the changes in the number and quality of these disruptions and to monitor the changes in patient sleep and outcome following our intervention.
Objective methods for diagnosing a predisposition to developing cancer, particularly lung cancer is described herein. The present invention provides a diagnostic method that utilizes the expression level of ERCC6L as an index of cancer. The present invention further provides methods of screening for therapeutic substances useful in the treatment of ERCC6L associated disease, such as a cancer, e.g. lung cancer. The invention further provides methods of inhibiting the cell growth and treating or alleviating one or more symptoms of ERCC6L associated diseases. The invention also features double stranded molecules, as well as vector and compositions containing them.
The current study examined the executive function (EF) deficits and their roles in reading in one hundred and four Cantonese-speaking children with typical development, reading disabilities (RD), ADHD, and comorbid ADHD and RD (ADHD + RD). Children's EF and reading skills were measured. Analysis of variance results showed that all children with disorders manifested deficits in verbal and visuospatial short-term and working memory and behavioral inhibition. Moreover, children with ADHD and ADHD + RD also exhibited deficits in inhibition (IC and BI) and cognitive flexibility. These findings demonstrated that the EF deficits in Chinese children with RD, ADHD, and ADHD + RD are similar to those in their counterparts using alphabetic languages. However, children with ADHD + RD displayed more severe deficits in visuospatial working memory compared to children with RD and ADHD, which was inconsistent with that observed in children using alphabetic languages. Regression analysis results showed that verbal short-term memory was a significant predictor for both word reading and reading fluency in children with RD and ADHD + RD. Moreover, behavioral inhibition significantly predicted reading fluency in children with ADHD. These findings also agreed with previous studies. Collectively, the results of the current study showed that the EF deficits and their roles in reading found in Chinese children with RD, ADHD, and ADHD + RD are mainly consistent with children using alphabetic languages. However, more studies are still needed to confirm these findings, especially comparing the severity of working memory among these three disorders.
In this study we sought to elucidate the therapeutic effects of fenchone on constipation-predominant irritable bowel syndrome (IBS-C) and the underlying mechanisms. An IBS-C model was established in rats by administration of ice water by gavage for 14 days. Fenchone increased the reduced body weight, number of fecal pellets, fecal moisture, and intestinal transit rate, and decreased the enhanced visceral hypersensitivity in the rat model of IBS-C. In addition, fenchone increased the serum content of excitatory neurotransmitters and decreased the serum content of inhibitory neurotransmitters in the IBS-C rat model. Meanwhile, western blot and immunofluorescence experiments indicated that fenchone increased the expressions of SCF and c-Kit. Furthermore, compared with the IBS-C model group, fenchone increased the relative abundance of Lactobacillus, Blautia, Allobaculum, Subdoligranulum, and Ruminococcaceae_UCG-008, and reduced the relative abundance of Bacteroides, Enterococcus, Alistipes, and Escherichia-Shigella on the genus level. Overall, fenchone ameliorates IBS-C via modulation of the SCF/c-Kit pathway and gut microbiota, and could therefore serve as a novel drug candidate against IBS-C.
Pellets comprise a dispersion of Aloe vera extract in a matrix composed of a collagen, gelatine fractionated gelatin, collagen hydrolysate and/or a gelatin deriv. (as matrix former). The matrix also contains up to 50 wt.% of an additional matrix former which is dextran, a sugar, glycine, lactose, sorbitol, mannitol and/or polyvinylpyrrolidone. The pellets have a grain size of 0.2-12mm and exists as a lyophilisate. USE/ADVANTAGE - Aloe vera is used as an antibiotic, to promote healing of wounds, to treat gastric ulcers, to soften skin, and as an antiinflammatory agent. The pellets are storage stable and concentrated, and have good skin tolerabilit